MAGNOLIA, Texas--(BUSINESS WIRE)--Pernix™ Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced that the Company does not expect its pediatric products Brovex® and Aldex® will be affected by the Food and Drug Administration announcement on March 2, 2011, to remove certain unapproved prescription cough, cold and allergy products from the U.S. market.
